AUS
NZ
UK
CA
USA
IND
Healthcare
Phase III Study of Nasal Polyps Treatment Celebrated by GSK
October 14, 2024 05:03 AM PDT| By Team Kalkine MediaHighlights:,GSK PLC reports positive outcomes from two pivotal clinical trials (ANCHOR-1 and ANCHOR-2) evaluating depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP).,Participants receiving depemokimab demonstrated significant reduction...
Jasper Therapeutics Shares Encouraging Data from SPOTLIGHT Study on Briquilimab for Chronic Inducible Urticaria
October 14, 2024 04:23 AM PDT| By Team Kalkine MediaHighlights:,Jasper Therapeutics announced promising results from its SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab for chronic inducible urticaria (CIndU).,A clinical response was observed in 93% of participants within six weeks, with 83% o...
Why Is Royalty Pharma Maintaining Its Dividend?
October 14, 2024 04:15 AM PDT| By Team Kalkine MediaHighlights,Royalty Pharma plc is set to distribute a dividend on December 10th.,The dividend amount is $0.21 per share.,The company's dividend yield stands above the industry average.,Royalty Pharma plc,(NASDAQ:RPRX),operates within the healthcare an...
BARDA Funding Secured by RedHill Biopharma to Enhance Opaganib Development for Ebola Treatment
October 14, 2024 04:14 AM PDT| By Team Kalkine MediaHighlights:,RedHill Biopharma has secured funding from BARDA to advance the development of opaganib as a treatment for Ebola virus disease (EBOV).,Recent studies funded by the U.S. Army demonstrated that opaganib significantly improved survival rates...
Bicycle Therapeutics (BCYC) Climbs 5.7%: Further Upside Evaluated
October 14, 2024 03:55 AM PDT| By Team Kalkine MediaHighlights:,Bicycle Therapeutics PLC (BCYC) shares rose 5.7% to close at $26.46, supported by significantly increased trading volume.,The company's lead drug, zelenectide pevedotin, is currently undergoing evaluation in the phase II/III Duravelo-2 st...
Strategic Deal Between Lundbeck and Longboard Pharmaceuticals Aims to Enrich Neuroscience Pipeline
October 14, 2024 03:34 AM PDT| By Team Kalkine MediaHighlights:,Lundbeck has announced the acquisition of Longboard Pharmaceuticals to strengthen its neuroscience pipeline, valued at approximately USD 2.6 billion.,The deal will integrate the innovative product bexicaserin, currently in late-stage deve...
Why Did Nurix Therapeutics Exceed Profit Targets Amid Lower Revenue?
October 14, 2024 03:18 AM PDT| By Team Kalkine MediaHighlights:,Nurix Therapeutics focuses on targeted protein modulation therapies.,Q3 GAAP earnings per share (EPS) showed a reduction, but outperformed expectations.,The company reported a decrease in revenue compared to the previous year.,Nurix Thera...
Innate Pharma's Executive Board Welcomes Jonathan Dickinson as New CEO
October 14, 2024 03:00 AM PDT| By Team Kalkine MediaHighlights:,Innate Pharma has appointed Jonathan Dickinson as its new Chief Executive Officer and Chairman of the Executive Board, effective November 1, 2024.,Dickinson brings a wealth of experience from senior leadership roles at prominent biotech a...
PacBio Partners with National Cancer Centre Singapore for Cancer Research
October 11, 2024 03:19 PM PDT| By Team Kalkine MediaHighlights,PacBio and the National Cancer Centre of Singapore (NCCS) have entered a research collaboration aimed at advancing cancer research using cutting-edge sequencing technologies.,The collaboration will combine PacBio's Onso short-read and Kinn...
Is Myriad Genetics Poised for Growth?
October 11, 2024 02:46 PM PDT| By Team Kalkine MediaHighlights,Multiple insider transactions, including significant transactions, have been observed at Myriad Genetics, Inc. over the past year, drawing attention from shareholders.,Insider selling can carry different meanings, but when key executives,...
Cardiol Therapeutics is advancing clinical trials of its pure cannabidiol product, CardiolRx, for inflammatory heart disease treatment
October 11, 2024 12:56 PM PDT| By Team Kalkine MediaHighlights,Cardiol Therapeutics Inc. is focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with a lead candidate in clinical trials.,The company has successfully raised $15.5 million through a public offering to ad...
Aetna Celebrates 88% of Medicare Advantage Members in 4-Star or Higher Plans for 2025
October 11, 2024 02:05 AM PDT| By Team Kalkine MediaHighlights,Aetna, a CVS Health company, reports that 88% of its Medicare Advantage members are enrolled in plans rated 4 stars or higher for 2025, with 68% in 4.5-star plans.,The company achieved its highest-ever member experience score since the inc...
Clover Health's PPO Medicare Advantage Plans Achieve High Rating for 2025
October 11, 2024 01:59 AM PDT| By Team Kalkine MediaHighlights,Clover Health’s PPO Medicare Advantage plans have received a Star rating increase to 4 Stars for 2025, impacting payment year 2026.,The HMO Medicare Advantage plan rating has also risen to 3.5 Stars, with over 95% of Clover’s Medicare Adva...
Is Pfizer's Dividend a Sign of Strength?
October 10, 2024 03:26 PM PDT| By Team Kalkine MediaHighlights:,Pfizer’s long-standing commitment to shareholder value is reaffirmed with its 344th consecutive quarterly dividend, underlining the company's consistency in returning profits to shareholders.,The announcement demonstrates the company's fi...
Tempest Enters Agreement with Roche to Progress Amezalpat Therapy in Hepatocellular Carcinoma
October 10, 2024 05:33 AM PDT| By Team Kalkine MediaHighlights:,Tempest Therapeutics has entered into an agreement with Roche to advance amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepato...
Brokers Acknowledge GSK's Zantac Settlement as a 'Positive Development'
October 10, 2024 05:22 AM PDT| By Team Kalkine MediaHighlights:,GSK PLC has reached a $2.2 billion settlement that addresses 93% of the ongoing litigation related to its heartburn medication Zantac, which is viewed as a favorable outcome by analysts.,The settlement includes a $70 million payment to Va...
GSK Confirms $2.2 Billion Settlement for US Zantac Lawsuit
October 10, 2024 04:05 AM PDT| By Team Kalkine MediaHighlights:,GSK PLC has reached a settlement agreement of up to $2.2 billion to resolve approximately 80,000 lawsuits related to its heartburn medication Zantac.,The settlement will address 93% of state court cases, with completion anticipated by mid...
Cardiol Therapeutics has confirmed the pricing of its public offering at $13.5 million
October 09, 2024 06:20 AM PDT| By Team Kalkine MediaHighlights:,Cardiol Therapeutics is raising US$13.5 million through a public offering of 8,437,500 Class A common shares at a price of $1.60 per share.,Proceeds from the offering will primarily be directed towards advancing the clinical development o...
Clearside Biomedical has shared positive topline findings from its ODYSSEY Phase 2b trial of Suprachoroidal CLS-AX in wet AMD
October 09, 2024 05:30 AM PDT| By Team Kalkine MediaHighlights:,The ODYSSEY Phase 2b trial of CLS-AX demonstrated stable visual acuity and anatomical control over nine months.,The trial showed a positive safety profile with no ocular or treatment-related serious adverse events reported.,A significant...
Haleon has benefited from an increase in sales estimates following UBS's revision of its long-term outlook
October 09, 2024 05:03 AM PDT| By Team Kalkine MediaHighlights:,Haleon PLC has been upgraded by UBS, with an increased price target of 445p, reflecting confidence in the company’s long-term revenue prospects.,Despite a 3% reduction in adjusted earnings due to foreign exchange fluctuations, UBS remains...
